4//SEC Filing
Humphrey David Carl 4
Accession 0001493152-21-016123
CIK 0001716947other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 7:15 PM ET
Size
5.6 KB
Accession
0001493152-21-016123
Insider Transaction Report
Form 4
Humphrey David Carl
Chief Financial Officer
Transactions
- Award
Common Stock
2021-06-30+50,000→ 50,000 total
Footnotes (1)
- [F1]On June 30, 2021, pursuant to that certain Agreement and Plan of Merger, dated January 31, 2021, among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Upon completion of the Merger, the Reporting Person received a grant of 50,000 restricted stock units, which, subject generally to the Reporting Person's continued employment through each such date would vest as to 20,000 restricted stock units on December 15, 2021, an additional 15,000 restricted stock units on December 15, 2022, and an additional 15,000 restricted stock units on December 15, 2023.
Documents
Issuer
Ensysce Biosciences, Inc.
CIK 0001716947
Entity typeother
Related Parties
1- filerCIK 0001708720
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 7:15 PM ET
- Size
- 5.6 KB